Indacaterol for Chronic Obstructive Pulmonary Disease (COPD)

Drugs of Today

Volumn 46, Issue 3, 2010, Pages 139-150

  Cazzola, Mario ^a   Proietto, A ^b   Matera, M G ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; INDACATEROL; MOXIFLOXACIN; ONBREZ; PLACEBO; SALBUTAMOL; SALMETEROL; SEROTONIN; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

BETA ADRENERGIC STIMULATION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG HALF LIFE; DRUG STRUCTURE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; INSPIRATORY CAPACITY; ISCHEMIC HEART DISEASE; LIPOPHILICITY; MUSCLE SPASM; NONHUMAN; PARESTHESIA; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SINGLE DRUG DOSE; SINUSITIS; SORE THROAT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT CONGESTION; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC BETA-AGONISTS; ADULT; ANIMALS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; INDANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 77954139628     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.3.1450070     Document Type: Review

References (49)

1. Celli, B.R., MacNee, W., Agusti, A. et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6): 932-46.
2. Rabe, K.F., Hurd, S., Anzueto, A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6): 532-55.
3. Vestbo, J., Anderson, J.A., Calverley, P.M. et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009, 64(11): 939-43.
4. Jones, C., Santanello, N.C., Boccuzzi, S.J., Wogen, J., Strub, P., Nelsen, L.M. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003, 40(1): 93-101.
5. Cazzola, M., Matera, M.G., Lótvall, J. Ultra long-acting beta2 agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14(7): 775-83.
6. Matera, M.G., Cazzola, M. Ultra-long-acting beta2-adrenoceptor agonists. An emerging therapeutic option for asthma and COPD? Drugs 2007, 67(4): 503-15.
7. Cazzota, M., Matera, M.G. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008, 155(3): 291-99.
8. Cazzola, M., Matera, M.G. Emerging inhaled bronchodilators: an update. Eur Respir J 2009, 34(3): 757-69.
9. Battram, C., Charlton, S.J., Cuenoud, B., et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1- hydroxy-ethyl)-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006, 317(2): 762-70.
10. Sturton, R.G., Trifilieff, A., Nicholson, A.G., Barnes, P.J. Pharmacological characterization of indacaterol, a novel once daily inhaled beta2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 2008, 324(1): 70-5.
11. Naline, E., Trifilieff, A., Fairhurst, R.A., Advenier, C., Molimard, M. Effect of indacaterol, a novel long acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007, 29(3): 575-81.
12. Battram, C., Li, J., Coulthard, A., Hardaker, L., Poll, C., Askey-Sarvar, A., Trifilieff, A. Indacaterol does not blunt the effect of salbutamol in vivo. Am J Respir Crit Care Med 2009, 179(Suppl.): Abst 2075.
13. Lombardi, D., Cuenoud, B., Krämer, S.D. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009, 38(5): 533-47.
14. Tarral, A., Fauchoux, N., Knight, H., Perry, S., Wood, J., Brookman, L. Safety and tolerability of multiple-dose indacaterol, a novel beta2-agontst, in patients with mild asthma. Eur Respir J 2005, 26(Suppl.): Abst 253S.
15. Duvauchelle, T., Elharrar, B., Knight, H., Krebbs-Brown, A., Perry, S. Single-dose indacaterol, a novel 24-h beta2-agonist, is well tolerated in patients with mild asthma. Eur Respir J 2005, 26(Suppl.): Abst 253S.
16. Chuchalin, A.G., Tsoi, A.N., Richter, K., Krug, N., Dahl, R., Luursema, P.B. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 2007, 101(10): 2065-75.
17. Aubier, M., Duval, X., Knight, H. et al. Indacaterol, a novel once-daily beta2-agonist, is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD. Eur Respir J 2005, 26(Suppl.): Abst 287S.
18. Bauwens, O., Ninane, V., Van de Maele, B., Firth, R., Dong, F., Owen, R., Higgins, M. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009, 25(2): 463-70.
19. Kato, M., Fukuchi, Y., Hosoe, M., Emery, C., Higgins, M., Kramer, B. Sustained 24-h bronchodilator efficacy of single doses of indacaterol in Japanese COPD patients. Am J Respir Crit Care Med 2009, 179(Suppl.): Abst 2462.
20. LaForce, C., Janssens, E., de Teresa Parreno, L. et al. Sustained 24-hour efficacy of once-daily indacaterol in patients with COPD. Chest 2009, 136(Suppl.): Abst 94S.
21. Balint, B., Watz, H., Amos, C., Owen, R., Kramer, B., Higgins, M. Fast onset of bronchodilation with indacaterol in patients with COPD. Eur Respir J 2009, 34(Suppl.): Abst 779S.
22. Beier, J., Beeh, K.M., Brookman, L., Peachey, G., Hmissi, A., Pascoe, S. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009, 22(6): 492-6.
23. Rennard, S., Bantje, T., Centanni, S., et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008, 102(7): 1033-44.
24. Magnussen, H., Verkindre, C., Jack, D., Jadayel, D., Owen, R., Higgins, M., Kramer, B. Indacaterol once-daily is equally effective dosed either in the evening or morning in COPD patients. Eur Respir J 2009, 34(Suppl.): Abst 779S.
25. Vogelmeier, C., Ramos-Barbon, D., Jack, D., Piggott, S., Owen, R., Higgins, M., Kramer, B. Once-daily indacaterol provides effective 24-hour bronchodilation in COPD: a double-blind comparison with tiotropium. Chest 2009, 136(Suppl.): 4S-g-5.
26. Beier, J., Chanez, P., Martinot, J.B., et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 2007, 20(6): 740-9.
27. Beeh K.-M., Khindri S., Eeg M., Drollmann A.-F. Effect of indacaterol maleate on dynamic lung hyperinflation in patients with COPD. Eur Respir J 2009, 34(Suppl.): Abst 778S.
28. Feldman, G., Siler, T., Prasad, N., Piggott, S., Owen, R., Higgins, M., Kramer, B. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a 12-week study. Eur Respir J 2009, 34(Suppl.): Abst 778S.
29. Fogarty, C., Hebert, J., Iqbal, A., Owen, R., Higgins, M., Kramer, B. Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium. Eur Respir J 2009, 34(Suppl.): Abst 345S.
30. Mahler, D., Palange, P., Iqbal, A., Owen, R., Higgins, M., Kramer, B. Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison. Eur Respir J 2009, 34(Suppl.): Abst 779S.
31. Yorgancioglu, A., Mahler, D., Iqbal, A., Owen, R., Higgins, M. Kramer, B. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 2009, 34(Suppl.): Abst 346S.
32. Lötvall, J., Cosio, B.G., Iqbal, A., Swales, J., Owen, R., Kramer, B., Higgins, M. Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium. Eur Respir J 2009, 34(SuppL): Abst 346S.
33. Rennard, S.I., Chapman, K.R., Luthra, A., Swales, J., Lassen, C., Owen, R., Kramer, B. Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD). Chest 2009, 136(Suppl.): 4S-f.
34. Kornmann, O., Luthra, A., Owen, R., Lassen, C., Kramer, B. Once-daily indacaterol provides superior bronchodilation, health status and clinical outcomes compared with salmeterol in patients with chronic obstructive COPD: a 26-week placebo-controlled study. Chest 2009, 136(Suppl.): Abst 152S.
35. Dahl, R., Kolman, P., Jack, D., Owen, R., Kramer, B., Higgins, M. Indacaterol once-daily provides sustained 24-hour bronchodilation over 52 weeks of treatment in COPD. Am J Respir Crit Care Med 2009, 179(Suppl.): Abst A4545.
36. Buhl, R., Pieters, W., Jack, D., Owen, R., Kramer, B., Higgins, M. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study. Eur Respir J 2009, 34(Suppl.): Abst 345S-6S.
37. Nonikov, V., Verkindre, C., Jack, D., Owen, R., Higgins, M., Kramer, B. Indacaterol once-daily reduces days of poor control in COPD over 52 weeks of treatment. Am J Respir Crit Care Med 2009, 179(Suppl.): Abst A6190.
38. Magnussen, H., Paggiaro, P., Jack, D., Owen, R., Higgins, M., Kramer, B. Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study. Eur Respir J 2009, 34(Suppl.): Abst 344S.
39. Buhl, R., Pieters, W., Jack, D., Owen, R., Kramer, B., Higgins, M. Indacaterol once-daily reduces COPD exacerbations over 52 weeks of treatment. Am J Respir Crit Care Med 2009; 179(Suppl.): Abst A6185.
40. Cazzola, M., Matera, M.G., Donner, C.F. Inhaled beta2-agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005, 65(12): 1595-1610.
41. Cazzola, M., Imperatore, F., Salzillo, A., Di Perna, F., Calderaro, F., Imperatore, A., Matera, M.G. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with pre-existing cardiac arrhythmias and hypoxoemia. Chest 1998, 114(2): 411-5.
42. Gupta, P., O'Mahony, M.S. Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing. Drugs Aging 2008, 25(5): 415-43.
43. Khindri, S., Sabo, R., Harris, S., Jennings, S., Drollmann, A.F. A thorough QT study on the effect of indacaterol on cardiac safety in healthy subjects. Am J Respir Crit Care Med 2009; 179(Suppl.): Abst A2463.
44. Worth, H., Kleerup, E., Iqbal, A., Owen, R., Kramer, B., Higgins, M. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur Respir J 2009, 34(Suppl.): Abst 346s.
45. Chung, K.F., Kornmann, O., Jack, D., Owen, R., Kramer, B., Higgins, M. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Am J Respir Crit Care Med 2009, 179(Suppl.): Abst A4546.
46. Cazzola, M., Tashkin, D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009, 6(5): 404-15.
47. van Noord, J.A., Buhl, R., LaForce, C., Martin, C., Jones, F., Dolker, M., Overend, T. Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD. Eur Respir J 2009, 34(Suppl.): Abst 776S.
48. Fabbri, L.M., Van de Maele, B., Lemmens, B., Martin, C., Horton, R., Dolker, M., Overend, T. Cardiovascular safety of QVA149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD. Eur Respir J 2009, 34(Suppl.): Abst 346S.
49. Onbrez Breezhaler. Summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/onbrez-breezhaler/ emea-combined-h1114en.pdf. Date last accessed: January 29, 2010.